Pain company Afferent completes $23mm Series A round
Third Rock Ventures and Pappas Ventures have the led the Series A financing of chronic pain start-up Afferent Pharmaceuticals, which received $23mm. Domain Associates and New Leaf Venture Partners also invested. Each VC is represented on the company's board.
- Venture Financing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.